Low dose group, 2 × 1 mg PAC | High dose group, 2 × 18.5 mg PAC | Incidence rate ratio (95% CI) p value | |
---|---|---|---|
Participants with less than 5 UTIs in the 12 months preceding enrolment | n = 46 | n = 51 | |
Number of symptomatic UTI | 39 | 21 | |
Symptomatic UTI, age-adjusted incidence density (95% CI)a | 2.29 (1.66–3.16) | 1.32 (0.81–2.13) | 0.57 (0.33–0.99) p = 0.048 |
Participants with 5 UTIs or more in the 12 months preceding enrolment | n = 27 | n = 21 | |
Number of symptomatic UTI | 20 | 24 | |
Symptomatic UTI, age-adjusted incidence density (95% CI)a | 2.23 (1.37–3.61) | 3.34 (1.96–5.68) | 1.50 (0.81–2.76) p = 0.195 |